entertainment -WSS

entertainment

author：Wikipedia 2025-09-05 13:47:33 - browse：14816

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into the fast-growing field of using targeted doses of radiation to treat cancer.

RayzeBio, which raised about $350 million in a September initial public offering, is working in radiopharmaceuticals, which pair the tumor-killing power of radiation with the precision of targeted cancer therapies. The company is currently running a pivotal trial of its most advanced drug, RYZ101, in neuroendocrine cancer and has a pipeline of treatments for kidney, liver, and other cancers.

Bristol Myers will pay $62.50 in cash per share of RayzeBio, a roughly 115% premium to the company’s recent trading and more than triple the company’s IPO price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： As H5N1 spreads in cows, experts warn against drinking raw milk

explore

focus

WSS

STAT reporters are Pulitzer Prize finalists for investigative reporting

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

As H5N1 spreads in cows, experts warn against drinking raw milk

Oak Street deal isn't the answer to health care's woes

Hottest summer in 2,000 years puts focus on extreme heat, health

ALS treatment from Biogen, Ionis fails in study

knowledge

entertainment

entertainment

Dobbs anniversary: the lost opportunity of abortion as health care

Oak Street deal isn't the answer to health care's woes

Drug repurposing or repositioning? The language matters

STAT series 'Denied by AI' wins major journalism prizes

How one medical school became remarkably diverse

Supreme Court to hear if Covid misinformation is protected speech

George Santos makes 1st court appearance after pleading not guilty to 13 counts

The United States must get value

Drug repurposing or repositioning? The language matters

Obesity drug from Roche shows promise in early study

focus

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

Fertility clinic egg and embryo storage is a disaster

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

The White House hikes tariffs on plastic syringes made in China

HHS suspends federal funding for EcoHealth Alliance

ALS treatment from Biogen, Ionis fails in study

explore

explore

focus

focus